Ioannis Lempesis, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Oxygen Consumption | 2 | 2024 | 1867 | 1.020 |
Why?
|
| Adipocytes | 4 | 2024 | 1190 | 0.980 |
Why?
|
| Cell Respiration | 1 | 2024 | 201 | 0.910 |
Why?
|
| Adipose Tissue | 5 | 2024 | 3313 | 0.900 |
Why?
|
| Adipokines | 2 | 2023 | 307 | 0.890 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2023 | 278 | 0.800 |
Why?
|
| Blood Circulation | 1 | 2021 | 248 | 0.720 |
Why?
|
| Obesity | 12 | 2024 | 12939 | 0.700 |
Why?
|
| Endometriosis | 3 | 2022 | 870 | 0.660 |
Why?
|
| Oxygen | 2 | 2022 | 4227 | 0.650 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2023 | 376 | 0.630 |
Why?
|
| Melatonin | 1 | 2024 | 668 | 0.610 |
Why?
|
| Leptin | 2 | 2023 | 1595 | 0.590 |
Why?
|
| Peripheral Arterial Disease | 2 | 2023 | 1275 | 0.470 |
Why?
|
| Mitochondria | 1 | 2024 | 3620 | 0.370 |
Why?
|
| Insulin Resistance | 1 | 2023 | 3952 | 0.330 |
Why?
|
| Oxidative Phosphorylation | 1 | 2024 | 495 | 0.200 |
Why?
|
| Body Fat Distribution | 1 | 2023 | 245 | 0.190 |
Why?
|
| Dysmenorrhea | 1 | 2022 | 98 | 0.190 |
Why?
|
| Adipose Tissue, White | 1 | 2024 | 362 | 0.190 |
Why?
|
| Cardiovascular Diseases | 2 | 2023 | 15520 | 0.180 |
Why?
|
| Pelvic Pain | 1 | 2022 | 298 | 0.180 |
Why?
|
| Postprandial Period | 1 | 2021 | 314 | 0.170 |
Why?
|
| Ultrasonography, Doppler | 1 | 2021 | 462 | 0.160 |
Why?
|
| DNA, Mitochondrial | 1 | 2024 | 865 | 0.160 |
Why?
|
| Nutritional Support | 1 | 2020 | 173 | 0.160 |
Why?
|
| Anti-Obesity Agents | 1 | 2022 | 227 | 0.160 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2019 | 130 | 0.160 |
Why?
|
| Cell Death | 1 | 2023 | 1676 | 0.150 |
Why?
|
| Vitamin D | 2 | 2022 | 3301 | 0.140 |
Why?
|
| Receptors, Calcitriol | 1 | 2019 | 360 | 0.140 |
Why?
|
| Adiposity | 2 | 2024 | 1879 | 0.140 |
Why?
|
| Intra-Abdominal Fat | 1 | 2021 | 612 | 0.130 |
Why?
|
| Antioxidants | 1 | 2024 | 1667 | 0.130 |
Why?
|
| Postmenopause | 1 | 2024 | 2514 | 0.130 |
Why?
|
| Fasting | 1 | 2021 | 1603 | 0.120 |
Why?
|
| Femur | 1 | 2021 | 1308 | 0.120 |
Why?
|
| Humans | 18 | 2024 | 761208 | 0.120 |
Why?
|
| Neoplasms | 1 | 2023 | 22140 | 0.120 |
Why?
|
| Vitamins | 1 | 2022 | 1634 | 0.120 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 1111 | 0.110 |
Why?
|
| Ultrasonography, Interventional | 1 | 2021 | 1496 | 0.110 |
Why?
|
| Energy Metabolism | 1 | 2024 | 2877 | 0.110 |
Why?
|
| Apomorphine | 1 | 2012 | 149 | 0.100 |
Why?
|
| Nutritional Status | 1 | 2020 | 1597 | 0.100 |
Why?
|
| Homeostasis | 1 | 2023 | 3320 | 0.100 |
Why?
|
| Female | 9 | 2024 | 392544 | 0.090 |
Why?
|
| Glucose | 2 | 2022 | 4342 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2023 | 2293 | 0.090 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 1893 | 0.090 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 3873 | 0.090 |
Why?
|
| Dietary Supplements | 1 | 2022 | 3410 | 0.080 |
Why?
|
| Weight Loss | 1 | 2020 | 2680 | 0.080 |
Why?
|
| Mice, Knockout | 1 | 2024 | 14392 | 0.080 |
Why?
|
| Insulin | 1 | 2023 | 6588 | 0.080 |
Why?
|
| Feeding Behavior | 1 | 2020 | 3183 | 0.080 |
Why?
|
| Cell Proliferation | 1 | 2023 | 10422 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 4309 | 0.070 |
Why?
|
| Cell Differentiation | 1 | 2024 | 11509 | 0.070 |
Why?
|
| Liver | 1 | 2023 | 7514 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2023 | 12952 | 0.060 |
Why?
|
| Isoproterenol | 1 | 2024 | 396 | 0.060 |
Why?
|
| Fas Ligand Protein | 1 | 2024 | 216 | 0.060 |
Why?
|
| Pandemics | 1 | 2024 | 8663 | 0.060 |
Why?
|
| Animals | 4 | 2024 | 168079 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 26071 | 0.050 |
Why?
|
| Nitric Oxide | 1 | 2012 | 2136 | 0.050 |
Why?
|
| Inflammation | 1 | 2023 | 10759 | 0.050 |
Why?
|
| Memory | 1 | 2012 | 2190 | 0.050 |
Why?
|
| Risk Factors | 3 | 2024 | 74239 | 0.050 |
Why?
|
| Aged | 2 | 2024 | 169288 | 0.050 |
Why?
|
| Ascitic Fluid | 1 | 2021 | 189 | 0.050 |
Why?
|
| Follicular Fluid | 1 | 2021 | 92 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2024 | 13385 | 0.040 |
Why?
|
| Ion Channels | 1 | 2024 | 1038 | 0.040 |
Why?
|
| Middle Aged | 2 | 2024 | 220853 | 0.040 |
Why?
|
| Mitochondrial Proteins | 1 | 2024 | 974 | 0.040 |
Why?
|
| Adipose Tissue, Brown | 1 | 2024 | 766 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 12159 | 0.040 |
Why?
|
| Sodium | 1 | 2022 | 1589 | 0.030 |
Why?
|
| Weight Gain | 1 | 2024 | 2349 | 0.030 |
Why?
|
| Motivation | 1 | 2023 | 2002 | 0.030 |
Why?
|
| Nitric Oxide Donors | 1 | 2012 | 126 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2022 | 3089 | 0.020 |
Why?
|
| Nitric Oxide Synthase | 1 | 2012 | 908 | 0.020 |
Why?
|
| Male | 3 | 2024 | 360693 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2012 | 1848 | 0.020 |
Why?
|
| Smoking | 1 | 2024 | 9055 | 0.020 |
Why?
|
| Adult | 1 | 2021 | 221119 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2024 | 22127 | 0.020 |
Why?
|
| Prognosis | 1 | 2024 | 29687 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2021 | 22174 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2020 | 24021 | 0.010 |
Why?
|
| Mice | 1 | 2024 | 81326 | 0.010 |
Why?
|
| Rats | 1 | 2012 | 23704 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2020 | 64681 | 0.010 |
Why?
|